Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. - Wikidata - awgldk - TriplyDB

Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.

Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.

http://www.wikidata.org/entity/Q47931535

about

Targeting the adaptive molecular landscape of castration-resistant prostate cancer Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.SEOM clinical guidelines for the treatment of metastatic prostate cancer GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone.Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies.Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer Advances in systemic therapies for metastatic castration-resistant prostate cancer.Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.Drug therapies for metastatic castration-resistant prostate cancer.Novel agents for castration-resistant prostate cancer: Early experience and beyond.What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?Role of taxanes in advanced prostate cancer.Anti prostate cancer using PEGylated bombesin containing, cabazitaxel loading nano-sized drug delivery system.Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.Contemporary agents in the management of metastatic castration-resistant prostate cancer.Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer.Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations.Cabazitaxel for the therapy of metastatic castration-resistant prostate cancer in the aftermath of the CHAARTED trial.The evolution of chemotherapy for the treatment of prostate cancer.Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents.Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer.Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer.Current treatment strategies for advanced prostate cancer.The prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel.APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer.Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience.Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel.

P2860

Q27022821-2E138D47-5027-468F-B1C2-92E7BE7B4402 Q28075965-034E213F-6B94-4D35-9716-0A6CC3C9D3A1 Q30244818-CE087EB3-230C-4F5C-B5FF-E68194CF710F Q34553405-6C97152B-50AE-4D20-989C-6E4A0F12CE3F Q35795342-8F5C4E8C-0428-4B9C-88D6-39BF24F28129 Q35879087-913BCEF1-4872-4BED-9E30-C664818F2FB5 Q36410270-BC29448D-CB82-469E-BB12-AD863171075C Q36586089-49EDABB8-CF9C-4504-9078-A116AB93D9C2 Q36823062-3FBB28CC-772D-4578-88D6-E333BB2318E8 Q37726362-1776E389-BDF0-4DA9-8396-DC542EB2C37F Q37735587-53E80E98-19BA-409A-B5B1-5F4E2330313D Q38232184-51BD8D77-8B05-46FC-87F8-124F6DAEDCD3 Q38244522-441E0A06-9BE7-4BC5-9694-A4C420905ECF Q38276818-99AEB8E2-4A30-4AF5-A198-7318203FA83A Q38282461-65D69E37-0468-4E28-9D62-F2A2B79E0EFD Q38530028-2B49BBAC-D98A-41C2-BDE2-D3CE68EC4D7A Q38566800-CD5A8032-DC51-4EFB-978A-E6672774383D Q38574684-A70688AA-75F3-467C-B09E-28AC9A8CC2D8 Q38587547-1A815911-CD50-48FA-88A4-9AC230C98F66 Q38726366-69E6092D-B7E7-4910-BCE4-D36FE8AEA542 Q38773368-6EC5B86D-562C-4533-9E5F-E2046A80024E Q38797560-D470C372-BFEC-4B05-80F0-56C8C3449D4A Q38865487-A6EB3D76-D1B9-435F-90D8-0449F27EF6DF Q39016544-296CCEED-2BEC-4D93-9BC0-CF45A0C58EC0 Q39092924-55127764-1BF9-48F6-AEBF-1AF2D1011F54 Q39205202-8F2197A0-9998-4FD0-BF89-6D987219E1F0 Q41332423-4FF80176-E4D8-4EE1-8029-C39C4F8D701F Q41484469-64F5B520-C038-4DDD-851F-05521971CDF7 Q44051061-FBE26A8B-3C42-482B-A5C9-A654B8172D37 Q45943517-C73AFCD7-28EC-4862-B17A-D6C43B292B46 Q46131083-27715DCD-355D-4EAB-8B66-FB1ACDF9E7FB Q47293703-782580D0-9E80-42B0-A53B-33B4EAABEDDE Q48037116-55B8F4E6-2B85-44B5-8312-7BC87B685503 Q48107095-459469F6-0106-4C53-8DC8-BE4C0D25DFDB Q48110667-A8C8C4A0-6B7F-4FD1-844D-83B6E928764A Q48561494-B8D24E9E-7EBE-4351-8C91-2C1A5B07DAC4 Q51746022-9BBAFA1B-27C0-4716-BD97-195476CA7199 Q52653007-D4DB6E21-106D-4964-AD0B-B0095F86ECF2 Q53737270-0E11CFE3-ABCC-4955-96D8-AFD8A3924D8C Q53822455-00DF4445-87A3-4938-97BA-F89E765468CA

P2860

Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.

http://www.wikidata.org/entity/Q47931535

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Activity of cabazitaxel in cas ...... t-generation endocrine agents.

@en

Activity of cabazitaxel in cas ...... t-generation endocrine agents.

@nl

type

label

Activity of cabazitaxel in cas ...... t-generation endocrine agents.

@en

Activity of cabazitaxel in cas ...... t-generation endocrine agents.

@nl

prefLabel

Activity of cabazitaxel in cas ...... t-generation endocrine agents.

@en

Activity of cabazitaxel in cas ...... t-generation endocrine agents.

@nl

P1433

Q47931535-0D334AF4-8E80-4A9B-A3E3-DAD16A8176BF

P1476

Q47931535-F171B3A0-18C3-4A15-A375-DB44B6DFE16C

P2093

Q47931535-3B3CA03F-0D6C-4B15-B70B-3D20E0636978

Q47931535-5529F647-EAFF-4F65-97A5-FBA000CE2F60

Q47931535-5F3F5EB6-C468-47E7-970B-97CDACBFA590

Q47931535-6CE6F949-A424-454A-B3D9-0EEDCCB86CB2

Q47931535-9C889FBC-0F77-4EC0-91F8-71872F938A01

Q47931535-D2AFA1B6-8C06-42B1-BC74-DFED5B8F4C38

Q47931535-ECD1C08A-3672-4116-8FF3-4FB2F7320D5E

P304

Q47931535-733A7837-7841-4584-84CD-783DE9703F8B

P31

Q47931535-8F87326B-787C-441C-A17C-A2D9C80AB18C

P356

Q47931535-396FEFBF-93C3-4A97-AF7C-132D3CF82926

P407

Q47931535-97A04A86-FA4B-47DB-88FB-65BE3E9D37FD

P433

Q47931535-4D84CD5B-5EC5-418A-975A-4B79D0351D44

P478

Q47931535-B23A9BF8-BD56-4025-923D-9F19C609B447

P50

Q47931535-2AA25D52-F489-4D73-A7D9-3A42A78A8A27

Q47931535-54EA9985-E4DD-4BE1-8D1D-E330FDC5814F

Q47931535-58A0C91C-5FD2-48C8-9A4B-18FD6E013573

P577

Q47931535-4494AF2C-3BD2-4A79-97A2-A58D41CD6FD0

P698

Q47931535-0457680B-A009-43BF-8239-620273CE3889

P356

J.EURURO.2013.11.044

P1433

European Urology

P1476

Activity of cabazitaxel in cas ...... t-generation endocrine agents.

@en

P2093

Aurelius G Omlin

http://www.w3.org/2001/XMLSchema#string

Carmel J Pezaro

http://www.w3.org/2001/XMLSchema#string

Christopher Parker

http://www.w3.org/2001/XMLSchema#string

David Dearnaley

http://www.w3.org/2001/XMLSchema#string

Diletta Bianchini

http://www.w3.org/2001/XMLSchema#string

Johann S de Bono

http://www.w3.org/2001/XMLSchema#string

Roberta Ferraldeschi

http://www.w3.org/2001/XMLSchema#string

P304

459-465

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2013.11.044

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

Gerhardt Attard

Amelia Altavilla

P577

2013-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24411987

http://www.w3.org/2001/XMLSchema#string